ArticleFrontiers in immunology2026
Case Report: Different faces of LRBA deficiency in five Moroccan families.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
LPS-responsive beige-like anchor protein (LRBA) deficiency is a primary immunodeficiency belonging to the spectrum of common variable immunodeficiency disorders, frequently associated with immune dysregulation, autoimmunity, and lymphoproliferation. Its clinical presentation is highly heterogeneous, ranging from isolated autoimmune cytopenias to severe multisystem involvement. Here, we report five cases of LRBA deficiency from five Moroccan families, highlighting the broad clinical variability of this condition. The first patient presented with chronic immune thrombocytopenic purpura (ITP) as the initial and predominant manifestation, associated with hypogammaglobulinemia. The second patient developed ITP complicated by a hemorrhagic syndrome and significant lymphoproliferation, including splenomegaly and hepatomegaly. The third patient initially presented with autoimmune hemolytic anemia (AIHA), followed by splenomegaly. The fourth patient exhibited a complex clinical course, beginning with bicytopenia and progressing to enteropathy, arthritis, pneumopathy, and type 1 diabetes mellitus, associated with splenomegaly, hepatomegaly, and lymphadenopathy. Finally, the fifth patient initially presented with ITP and subsequently developed bilateral panuveitis, arthritis, and recurrent respiratory infections. Targeted next-generation sequencing identified homozygous pathogenic variants in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.